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Abstract  
Purpose: Depression is a common problem in people with age-related macular 
degeneration (AMD) and diabetic retinopathy (DR). Antidepressants and 
psychotherapy are often underutilized. Our goal was to determine if self-care tools 
plus limited telephone support could reduce depressive symptoms.  
Methods: A single-blind randomized controlled clinical trial was conducted at 
Maisonneuve-Rosemont Hospital in Montreal, Canada. All eligible patients were 
invited to participate in the trial. To be eligible, participants must have had either late 
stage AMD or DR, at least mild depressive symptoms, and visual acuity better than 
20/200 in their better eye. Half were randomized to the intervention arm and half to 
delayed intervention/usual care. The intervention consisted of large print written and 
audio tools incorporating cognitive-behavioral principles plus three 10-minute 
telephone calls from a coach. Eight-week follow-up data were collected by telephone. 
The primary outcome was the 8-week change in depressive symptoms as measured 
by the Patient Health Questionnaire (PHQ-9). 
Results: Eighty participants, aged 50 years and older, were recruited while 10 were 
lost to follow-up (12.5%) giving 70 with complete data, 35 in each group. The mean 
baseline PHQ-9 score was 9.5 out of 27 (SD=3.9) indicating moderate depressive 
symptoms. The average decrease in PHQ-9 scores over the 8 weeks was 4.9 
(SD=4.2) in the intervention group and 3.2 (SD=4.6) in the usual care group, a 1.7 
point difference (P=0.104). After adjusting for baseline imbalances in visual acuity, 
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antidepressant use, and participation in psychotherapy, the difference increased from 
1.7 to 2.3 and became statistically significant (p=0.037). Sixty percent of those in the 
intervention group reported having used the tools at the end of the study. 
Conclusions: Self-care tools plus telephone coaching led to a small improvement in 
depressive symptoms in patients with age-related eye disease. Additional research 
into the best way to support depressed patients with age-related eye disease is 
necessary. 
Key Words: Depressive symptoms, Eye disease, Self-care tools, Randomized 
Controlled Trial  
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Résumé 
Objectif: La dépression est un problème fréquent chez les personnes atteintes de 
dégénérescence maculaire liée à l’âge (DMLA) et de rétinopathie diabétique (RD). 
Les antidépresseurs et les thérapies psychologiques sont souvent sous utilisés. Notre 
objectif était de déterminer si les outils d’auto-soins associés au support téléphonique 
limité pouvaient réduire les symptômes dépressifs. 
Méthodes: Un essai clinique randomisé à simple insu a été mené à l’Hôpital 
Maisonneuve Rosemont, Canada. Tous les patients éligibles étaient invités à 
participer à l’essai. Pour être éligibles, les participants devaient 1) avoir un diagnostic 
de DMLA avancée ou de RD, 2) au moins des symptômes dépressifs moyens et 3) 
une acuité visuelle meilleure que 20/200 dans leur meilleur œil. Une moitié des 
participants était randomisée au bras d’intervention et l’autre moitié à l’intervention 
retardée/traitement usuel.  
L’intervention était composée d’outils audio et écrits en gros caractères, incluant des 
principes cognitifs comportementaux plus trois appels téléphoniques d’un coach 
d’une durée de 10 minutes chacun. Les données de suivi étaient collectées huit 
semaines plus tard, par téléphone. L’issu primaire était le changement de symptômes 
dépressifs à huit semaines, mesuré par le questionnaire sur la santé du patient, PHQ-
9. 
Résultats: Quatre-vingts participants, âgés de 50 ans et plus  ont été recrutés, dont 
70 ayant des données complètes et 10 perdus de vue (12.5%). Le score moyen du 
iv 
 
PHQ-9 à l’inclusion était de 9.5 (SD=3.9) indiquant des symptômes dépressifs 
modérés. La réduction moyenne du score de PHQ-9 au terme du suivi était de 4.9 
(SD=4.2) dans le groupe d’intervention et de 3.2 (SD=4.6) dans le groupe de 
traitement usuel, soit une différence intergroupe de 1.7 point (p=0.104). Après avoir 
contrôlé pour les disparités observées à l’inclusion notamment pour l’acuité visuel, 
l’utilisation des antidépresseurs et la participation à la psychothérapie, cette 
différence est passée de 1.7 à 2.3 et est devenue statistiquement significative 
(p=0.037). Soixante pourcent des participants du groupe d’intervention ont rapporté 
avoir utilisé les outils d’auto-soins au terme de l’étude ou de l’exploitation des 
données  
Conclusion: Les outils d’auto-soins accompagnés de support téléphonique 
conduisent à une petite amélioration des symptômes dépressifs chez les patients 
atteints de pathologies oculaires liées à l’âge. Des recherches additionnelles ciblant 
les meilleures stratégies pour soutenir les patients déprimés atteints de maladies 
oculaires liées à l’âge sont nécessaires. 
Mots-clés: symptômes dépressifs, maladie oculaires, outils d’auto-soins, Essai 
randomisé contrôlé  
v 
 
Table of Contents  
Abstract ......................................................................................................................... i 
Résumé ....................................................................................................................... iii 
Table of Contents ......................................................................................................... v 
List of tables ............................................................................................................... vii 
List of figures ............................................................................................................. viii 
List of abbreviations ..................................................................................................... ix 
Dedication ................................................................................................................... xi 
Acknowledgements .................................................................................................... xii 
Chapter 1: Introduction ................................................................................................ 1 
1.1 The burden of depression .................................................................................. 1 
1.2 Risk factors for depression ................................................................................ 2 
1.3 Consequences of depression ............................................................................ 5 
1.4 Ocular diseases and depression in older populations ....................................... 6 
1.5 Treatments for depression ................................................................................. 7 
1.6 Limitations of current treatments ....................................................................... 9 
1.7 Specific objectives and hypotheses ................................................................. 10 
1.8 Significance of the study .................................................................................. 10 
Chapter 2: Literature review on self-management ..................................................... 11 
2.1 What is self-management? .............................................................................. 11 
2.2 Self-management and chronic diseases .......................................................... 12 
2.3 Self-management and depression ................................................................... 15 
2.4 Self-management, depression and eye diseases ............................................ 18 
vi 
 
2.5 Introduction to the project ................................................................................. 21 
Chapter 3: Methods and Results ............................................................................... 23 
3.1 Abstract ........................................................................................................... 24 
3.2 Introduction ...................................................................................................... 26 
3.3 Methods ........................................................................................................... 27 
3.4 Results ............................................................................................................. 33 
3.5 Discussion ....................................................................................................... 36 
Chapter 4: Discussion ............................................................................................... 43 
4.1 Self-care intervention for depression in old population with aged related eye 
diseases ................................................................................................................. 43 
4.2 Strength and limits of the study ....................................................................... 44 
4.3 Clinical implications and future research ......................................................... 46 
References ................................................................................................................ 49 
Appendices .................................................................................................................... i 
1. Patient Baseline Interview ................................................................................... i 
2. Follow-up questionnaire ................................................................................. xxiii 
 
 
vii 
 
List of tables 
Table 1: Baseline characteristics of participants by treatment assignment……….....42 
Table 2: Eight-week change values* by treatment assignment………………………..43 
Table 3: Use of tools by those in the intervention group according to coach………..44 
  
viii 
 
List of figures  
Figure1: Recruitment and retention flow chart…………………………………………...41 
 
  
ix 
 
List of abbreviations  
AIDS   Acquired Immune Deficiency Syndrome 
AMD   Age related Macular Degeneration  
ART    Antiretroviral Treatment 
BOMC  Blessed Orientation Memory –Concentration  
CBT   Cognitive Behavioral Therapy 
CD   Compact Disc 
CDC   Centers for Disease Control and Prevention  
CI   Confidence Interval  
CONSORT  Consolidated Standards of Reporting Trials 
COPD  Chronic Obstructive Pulmonary Disease 
DALY   Disability Adjusted Life Years  
DR   Diabetic Retinopathy 
DVD   Digital Versatile Disc 
GAD   Generalized Anxiety Disorder 
GDS-15  Geriatric Depression Scale 
HIV   Human Immunodeficiency Virus 
HMR   Hôpital Maisonneuve-Rosemont  
HR   Hazard Ratio 
IQR   Interquartile Range 
LogMAR  Log Minimum Angle of Resolution 
LSA   Life Space Assessment  
OD   Odds Ratio 
x 
 
p   p-value  
PHQ-9  Patient Health Questionnaire  
PST   Problem solving treatment  
RCT   Randomized Controlled Trial 
SD   Standard Deviation  
US   United States 
WHO    World Health Organization  
  
xi 
 
Dedication  
 
 
 
  
 
 
To Georgette, my sweet mother, for her love and continuous support  
  
xii 
 
Acknowledgements  
I first of all want to express my deepest and sincerest gratitude to Dr. Ellen 
Freeman for giving me the opportunity to strengthen my research skills and for being 
there whenever I needed her guidance. Dear Dr. Freeman, accept a special thanks 
from the bottom of my heart. 
I am also extremely fortunate to have experienced scientists like Dr. Kelley 
Kilpatrick and Dr. Benoit Tousignant to evaluate my project. I am grateful you could 
find time out of your busy schedule, to examine this work. 
My deepest thanks go to the entire research team, to all the participants and 
to the co-investigators of this project for their valuable contributions. I am sincerely 
grateful to you all. 
I would also like to thank the Maisonneuve Rosemont Hospital, the Antoine 
Turmel Foundation and the Fonds de Recherche du Quebec-Santé, for their financial 
support and without which this study would not have been possible. 
My gratitude also goes to Ms. Solmaz Moghadazadeh for her input into this 
project and especially, for spending quality time together throughout this Master’s 
degree period. Solmaz, it was a pleasure working with you. 
Lastly, for my lovely family and friends, to all those who participated in this 
project, even if you are not cited here, I am particularly grateful to you all. 
1 
 
Chapter 1: Introduction  
1.1 The burden of depression 
Depression is a major public health concern worldwide. Also known as major 
depressive disorder or clinical depression, depression is a mental illness affecting not 
only the mind but the body as a whole.(1) It refers to “a common mental disorder 
characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-
worth, disturbed sleep or appetite, feelings of tiredness and poor concentration”. (2) 
The disease is one of the major causes of disability in the world.(3) Approximately 
350 million people, predominantly women, are diagnosed with depressive symptoms 
around the world.(3) According to World Health Organization (WHO) estimates, it is 
one of the ten leading causes of disability adjusted life years (DALY) globally. If 
serious preventive measures are not taken to reduce the burden of the disease, 
depression could be among the top three causes of DALY’s by 2030.(3) 
 
In Canada, more than 2 million people are diagnosed with a mood disorder, 
one-third of them men. (4) Hospitalization for mood disorder is one and a half times 
more frequent  in women than in men (5) and about 11% of men and 16% of women 
in Canada will experience major depression in the course of their lives. (6) Using 
administrative data from three large Canadian employers, 25% of short-term disability 
claims were due to a nervous or mental disorder, 76% of which were depression-
related. (7)  The Canadian government spends approximately $51 billion dollars each 
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year for the treatment of the disease, specifically for primary care visits, 
hospitalizations, and medication. (8, 9) 
1.2  Risk factors for depression 
Some risk factors for depression have been identified. These include biological, 
genetic, socio-demographic, psychological, behavioral, and medical factors. (2, 10)   
1.2.1 Biological Factors  
Research findings indicate that insufficient levels of neurotransmitters or an 
imbalance of brain chemicals (e.g., dopamine, serotonin, and norepinephrine) in 
some people might trigger depressive symptoms. (11, 12)  Also, as a result of 
hormonal changes, some women may feel depressed after giving birth (13, 14) or at 
menopause. (15, 16) Some people experience depressive symptoms in the winter 
(seasonal affective disorder), possibly due to a lack of sunlight and vitamin D 
deficiency. (17-19) 
1.2.2 Genetic Factors  
Genetic factors play an important role in the aetiology of major depression as 
twin studies indicate a heritability of 40%-70% (20-22). Moreover, individuals with a 
family history of depression have an increased risk of suffering from depression 
compared to those with no immediate family member diagnosed with depressive 
symptoms. For example, a recent study revealed that individuals with an immediate 
family member diagnosed with depression are 2.8-10 times more at risk of developing 
depression. (23) However, no genes have yet been consistently identified. 
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1.2.3 Demographic Factors  
Female gender is a risk factor for depression. Many studies have revealed a 
higher rate of depressive symptoms in women compared to men.(24) Age is also 
associated with depression as studies have revealed a higher prevalence of major 
depression among older adults.(25, 26) Moreover, marital status is a risk factor as 
well: widowed, divorced and separated individuals tend to be diagnosed with 
depressive symptoms more frequently compare to married people or people who 
have never been married. (24, 27)  Furthermore, unemployed people and people with 
a relatively low annual income are more depressed compared to those making higher 
wages. (28, 29) Also, the disease tends to be more likely among urban residents 
versus rural residents. (30, 31) 
 Finally, some studies reported an association between race and major 
depression, especially among minority ethnic groups in the United States. Dunlop et 
al, in a study among preretirement Americans aged 54 to 65 years, indicated that 
African-Americans and Hispanics had an increased risk of being depressed 
compared to Whites, OR = 1.16 (95% CI 0.93-1.44) and OR=1.44 (95% CI 1.02-2.04) 
respectively (32). No major difference in depression rates has been observed among 
racial groups in Canada. However, a study carried out by Zheng and colleagues 
found a relatively better mental health condition among  Chinese, Asian and black 
Canadians  compared to white  English Canadians and that the mental health status 
of other racial or ethnic groups were similar to that of white English Canadians. (33) 
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1.2.4 Psychological and Social Factors   
People who experienced traumatic events during childhood might be more at 
risk of being depressed. For example, those who experienced sexual, physical or 
emotional abuse, who lost their parent or experienced parental divorce during this 
period, are more likely to be depressed.(34-37) Likewise, individuals who experienced 
negative life events such as divorce or loss of a loved one are at a higher risk of 
depression (38). Lack of social support also appears to be a risk factor. (31, 39, 40) 
1.2.5 Medical Factors    
Research has shown that some conditions are strongly associated with 
depression, namely hormonal imbalances, chronic viral infections, chronic pain, bone 
and connective tissue disease, neurological disease, respiratory disease, gastro-
intestinal disease, AIDS, cancer, heart disease, thyroid disorders, and eye disease 
(41-46). Similarly, medications may cause depressive symptoms. These include but 
are not limited to analgesic medications like Demerol and Percocet, contraceptives, 
acne and antihypertensive medication.(47, 48) 
1.2.6 Unhealthy behaviors  
Research findings have also revealed that some unhealthy behaviors are 
associated with depression. For example, alcohol and tobacco consumption seem to 
be related in a dynamic, bidirectional relationship with depressive symptoms (49, 50). 
Physical inactivity is also a risk factor (51) (52). People who do not exercise regularly 
5 
 
or who have limited physical activity are at a higher risk of being depressed. Likewise, 
poor sleep, less than 7 to 9 hours of sleep per night seems to be associated with 
depression (53-55). A cross sectional study carried out by Coulombe and other 
researchers indicated that sleep disturbances were strongly associated with 
depression (56). Conversely, sleep problems have been reported as a consequence 
of depression in some individuals (57, 58). 
1.3  Consequences of depression 
Depression can increase the risk of other chronic mental illnesses like bipolar 
disorder, generalized anxiety disorder and obsessive-compulsive disorder.(59-61) 
Second, depression may impair interpersonal relationships of people affected. 
Individuals suffering from depression tend to isolate themselves from peers; family or 
colleagues and this may affect their relationship with others. (62-64) Third, depression 
has been pointed out as one of the major risk factors of suicide (65). The Centers for 
Disease Control and Prevention (CDC) classified suicide as the 10th leading cause of 
death among all age groups in the US in 2012 (66, 67).  Fourth, depression is 
associated with worse life space, which is a measure of the spatial extent of a person 
over the last month. (68) Fifth, depression is associated with loss of productivity. 
Untreated depression was reported as having an impact on work and academic 
productivity.(69, 70) Dewa et al. carried out a study on depressive episodes and 
productivity among Canadian workers and found that untreated depressive symptoms 
have a highly negative impact on productivity.(71). For example, they found that the 
productivity loss of an organization where no one has access to treatment is five 
times that of an organization with access to depression related treatment. 
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Finally, depression is associated with an increased risk of death (72, 73). It is 
associated with mortality from heart disease, respiratory illness, cardiovascular 
disease, accidents, diabetes, nephritis, influenza, Alzheimer’s, septicemia, 
Parkinson’s and hypertension (45, 73-76). A meta-analysis carried out by Fan and 
colleagues in 2014 indicated that patients with major depression were at increased 
risk of all-cause mortality compared to non-depressive patients (HR = 1.98, 95% CI 
1.23-3.19). (45)  
1.4  Ocular diseases and depression in older populations  
Visual impairment is a serious concern for people aged 65 years and older.(77-
79) The prevalence of depression in older adults with visual impairment varies from 7 
to 39% for clinical depression and 29 to 43 % for depressive symptoms. (77, 80) 
Many studies indicated that depression is strongly associated with ocular diseases. 
(44, 81-86) 
In a recent cross-sectional study conducted in 2012, Popescu and colleagues 
(81) investigated the relationship between age related eye diseases and depression 
using the Geriatric Depression Scale (GDS-15). Three hundred and fifteen patients 
with age-related macular degeneration (AMD), Fuchs’ corneal dystrophy, or glaucoma 
were compared to 88 people with no significant vision loss. The prevalence rate of 
depressive symptoms ranged between 29-39% in the groups with eye disease 
compared to only 8% in the group without eye disease (P<0.05).  No changes were 
observed after adjustment for demographic, medical, and social factors. Furthermore, 
this research reported that limitations in life space and activity limitations due to a fear 
of falling mediated these relationships indicating that interventions that can help 
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people with eye disease to expand their mobility and maintain their activities may help 
to decrease the burden of depression in this population (81).  
Likewise, Casten et al, in summarizing research findings on depression and 
age-related macular degeneration found a depression prevalence of about 30 % 
among AMD patients and revealed that depression is a major cause of disability 
among older adults(82). Furthermore, a recent cross-sectional study on depression 
and mood indicators in glaucoma patients found that patients who reported worse 
visual function were more likely to be depressed.(83)  
Also, a prospective cohort study conducted by Sieu and colleagues on the 
association between depression and diabetic retinopathy suggested that diabetic 
patients with higher PHQ-9 depression scores have a significantly higher risk of 
developing diabetic retinopathy (OR=1.02; 95% CI; 1.00-1.05).(87). A study carried 
out in China among older adults with type 2 diabetes reported a high depression rate 
(35.7%). They did not have a control group but this rate is much higher than what is 
generally found in older adults .(88) 
1.5  Treatments for depression 
Psychotherapy and pharmacotherapy are two known treatment options 
available for depression. (3) Psychotherapy refers to psychological methods of 
treatment: “a treatment technique for certain forms of mental disorders relying 
principally on talk/conversation between the mental health professional and the 
patient” (89, 90) whereas pharmacology deals with the use of medication to treat the 
disease. The impact of pharmacotherapy or psychotherapy in depression treatment 
among children, adolescents, adults and elderly has been widely explored.(91, 92)  
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1.5.1 Combined pharmacotherapy and psychotherapy 
While some studies have focused exclusively on the impact of 
pharmacotherapy (92, 93) or psychotherapy (94, 95) on depressive symptoms, 
several studies have examined the use of both treatment methods on the reduction of 
depressive symptoms and argued that combined therapies are much more effective 
than monotherapy (psychotherapy or pharmacotherapy alone).  
Meta-analyses carried out on the topic revealed that both treatments have 
similar success rates, while emphasizing that psychotherapy may be more effective 
over the long-term. (96) In a meta-analysis, Cuijpers et al. investigated the effect of 
psychotherapy on pharmacotherapy treatment to reduce depressive disorders in adult 
patients. The result of the study revealed that psychotherapy has an added value 
compared to pharmacotherapy alone in depression treatment.(89) 
Gerson and colleagues conducted a meta-analysis on published data 
comparing treatment rate response and tolerability of pharmacological and 
psychological treatments for depression among older adults aged 55 years and 
above. The result of the study did not indicate any significant difference in the 
response rates between the different types of treatment. (80) Finally, another meta-
analysis looked at the effectiveness of psychotherapy compared to pharmacotherapy 
in older depressed patients. Only studies based on pharmacotherapeutic or 
psychotherapeutic interventions versus control (placebo or waiting list) were included 
in the analysis. The findings indicated that the effectiveness of both treatments were 
similar regarding the improvement of depression symptoms in this population. (81) 
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1.6  Limitations of current treatments 
Despite the existence of pharmacological and psychological therapies, many 
depressed people remain undiagnosed and do not receive treatment. Of those who 
do receive treatment, side effects result in high rates of discontinuation of 
antidepressants as 50% of new users discontinued within 6 months in a group of over 
90,000 Australian veterans.(97) Research indicates that if given the preference, 
adults with depression prefer psychotherapy to antidepressants by a 2:1 ratio (CI, 1.6 
to 2.7, p=. 001) (98) A study found preference to be an important contributor to 
treatment success as those who had higher preference scores for psychotherapy 
compared to antidepressants were more likely to drop out of treatment in a trial of 100 
patients with major depressive disorder (99). However, psychotherapy is often 
expensive in the private system and there are long waits in the public system as it is 
provided at no cost and there are often not enough therapists to meet demand. 
Psychotherapy in the private healthcare system is expensive; wait times in the public 
system can be very long. As an example, an hour-long session in the private services 
varies from 50 to 240 Canadians dollars and is only covered by some private 
insurance plans (100, 101).  
Alternative strategies for delivering treatment to adults with depression are 
needed, particularly for vulnerable and often isolated populations like older adults with 
vision problems. Therefore, we propose to investigate the use of self-care tools, 
which will allow people with depression to take care of themselves in the privacy of 
their own home. 
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1.7  Specific objectives and hypotheses  
The main objective of this study is to determine the short-term effect of a self-
care intervention on depression in patients with age-related ocular diseases, namely 
age-related macular degeneration and diabetic retinopathy. We hypothesized that the 
use of self-care tools would reduce depressive symptoms in these patients.  The 
secondary objectives will be to 1) examine the effects of the intervention on anxiety 
symptoms, life space, and self-efficacy, 2) examine whether the effects of the 
intervention vary by patient characteristics such as socio-demographic factors, 
physical health, severity of vision loss, eye disease, and level of self-efficacy. 
1.8  Significance of the study 
This study is the first to investigate self-care tools in patients with age-related 
eye disease. The research findings could result in the availability of a low-cost, 
efficacious intervention that could be widely offered within ophthalmology or 
optometry clinics and low vision rehabilitation agencies to reduce the burden of 
depression in those with age-related eye disease. It may reduce depressive 
symptoms by itself or it may also encourage the patient to speak to his or her 
physician and discuss other treatment options for depression. If patients with age-
related eye disease have their mental health under control, they will likely be better 
able to comply with their prescribed treatment regimens leading to better vision 
outcomes. 
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Chapter 2: Literature review on self-management 
2.1  What is self-management?  
Self-management, also known as patient empowerment, or self-care, refers to 
an individual’s ability to manage the symptoms, treatment, physical, psychosocial, 
and lifestyle changes inherent in living with a chronic condition. (102) It could also be 
considered as “a treatment that combines biological, psychological and social 
intervention techniques, with a goal of maximal functioning of regulatory processes.” 
(103).  
There are three main tasks associated with self-management. These include 
medical management, emotional management and role management (104-106). 
Medical management refers to activities like taking medication, adhering to a special 
diet or using an inhaler. The second task involves managing emotions like anger, 
fear, frustration, and depression that can occur when faced with a chronic disease. 
The last task deals with changing, creating or maintaining new behaviors or life roles 
(104). Moreover, self-management education provides patients with 6 types of skills, 
namely:  
 Problem solving: how to generate possible solutions to 
circumstances they are facing 
 Decision-making provide them with useful knowledge in order to 
take action and improve their situation 
12 
 
 Resource utilisation teach patients how to use the available 
resources  
 Partnership with health care providers trains and prepares 
patients how to communicate efficiently with their health care provider. 
 Action planning: provides patient with information on how to take 
action in order to change a particular behavior 
 Self-tailoring or self-efficacy gives patients the confidence to carry 
out activities necessary to reach a desired goal 
Research indicates that patients can change the progression of their disease 
and become able to handle their own health if given proper training and support. 
(104,105) This implies involving patients in the management of their disease including 
the medical, behavioural, and emotional aspects.  
In general, self-management interventions are defined as requiring less than 
three hours of professional support and can be delivered in person, by telephone, 
over the internet, in a one-on-one or group session (107). This treatment strategy has 
been widely used in healthcare settings, particularly in those with chronic disease. 
2.2  Self-management and chronic diseases  
The study of self-management interventions for some chronic diseases has 
been widely explored. Much work has been done in the fields of cardiovascular 
disease, pain, and HIV. For example, a systematic review was recently conducted to 
examine the effectiveness of mobile health wireless device (mHealth) interventions on 
behavioural lifestyle changes and medication adherence for cardiovascular disease 
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self-management using data from seven clinical trials.  (108) Three trials showed that 
text messaging could improve medication adherence and two trials showed that text 
messaging could improve physical activity but no significant results were seen on 
dietary behavior or smoking cessation. This systematic review suggested that 
mHealth was effective in changing certain lifestyle behaviours among a 
cardiovascular disease population. 
In the field of podiatry, a randomized clinical trial was carried out to explore 
the clinical and cost effectiveness of a patient self-management program for basic 
foot care among older adults over a 6-month period. (109) Seventy-eight participants 
were randomized to receive the self-management treatment and 75 to the usual care, 
which was self-referral to a podiatry department. At the end of the study, participants 
in the intervention group had lower foot disability scores compare to the usual care 
group. A 1-unit score difference was observed between the two arms, (95% C.I. -2, 
0). No cost difference was observed between the two treatment regimens indicating 
that self-management had better outcomes for a similar cost.  
Similarly, Miaskowski and colleagues examined the effectiveness of a self-
care intervention to improve cancer pain management in a randomized controlled 
clinical trial. Patients receiving a psycho-educational intervention (n=93) were 
compared to those under standard care (n=81) (patient version of the Cancer Pain 
Guideline published by the Agency for Health Care Policy and Research (AHCPR)). 
Those in the intervention arm were taught how to use a pillbox and were given 
information on how to communicate with their doctor about their pain and eventual 
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changes in their prescriptions. In addition, two follow-up home visits and three phone 
calls were offered by a coaching nurse to both arms. The result of the study showed a 
reduction in pain intensity scores in the intervention arm compared to the standard 
care arm (110). 
Concerning HIV, several self-management interventions have been 
conducted, as people with deadly must take their medication as prescribed for many 
years. (111) For example, a recent quasi-experimental study compared the 
effectiveness of a virtual self-management intervention versus traditional follow-up 
among people living with HIV over a period of 3 to 4 months. The intervention (n=99) 
consisted of four virtual nurse intervention (interactive) sessions, each 20-30 minutes 
long. The control or traditional follow-up (n=80) was based on a face-to-face meeting 
with health care professionals.  
The comparison was made with regard to self-reported adherence to 
antiretroviral treatment (ART). Selected participants were on ART treatment for 11 
years (111). Medication adherence was the primary outcome. The authors also 
looked at self-efficacy, attitude toward medication intake, symptom-related discomfort, 
stress, and social support. Adherence at baseline was high, 80 and 84 % respectively 
for the traditional and virtual follow-up groups. The results of the study indicated a 
significant adherence improvement in both groups but non differential by group at six 
months, 93% for the traditional group and 90% for the virtual group. 
Similarly, Millard and colleagues conducted a systematic review on self-
management education programs among people living with HIV/AIDS (112).This 
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review indicated that self-care programs resulted in short term improvements in 
physical, psychosocial, health knowledge and behavioral outcomes in this population. 
In most studies included in the review, the improvements were highly significant in the 
intervention group compared to the control (112). 
To conclude, there is evidence that self-care interventions can result in 
improvements in chronic disease care. However, more rigorous studies are needed 
that consistently use randomized controlled trial designs, blinded data collection, and 
that examine longer-term outcomes. 
2.3  Self-management and depression  
Self-management interventions including qualitative studies and randomized 
controlled trial studies have also been evaluated for depression. For example, 
Grieken et al explored depression recovery strategies among patients. Focus group 
discussions were organised to collect patients’ opinions. The findings indicated that 
being engaged in activities, contact with fellow sufferers, proactive attitude towards 
the disease and treatment were, among others, strategies which could help patients 
recovering from the disease (112). 
Several clinical trials have been done. For example, McCusker et al (113) 
examined a telephone-supported depression self-care intervention in 223 self-
referred adult patients with chronic physical illnesses but not eye disease. Patients 
were assigned to either the intervention group (toolkit including Antidepressant Skills 
Workbook in paper and audio versions, a mood monitoring tool and an informational 
DVD plus telephone coaching) or to the control group (toolkit without coaching). PHQ-
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9 scores declined significantly in both groups over the 6-month follow-up.  The PHQ-9 
scores were significantly lower at 3 months in the intervention group but not at 6 
months indicating that coaching was helpful at first but that the effect then diminished 
over time.  The effect sizes at 3 and 6 months were 0.44, 95% CI =0.16-0.72 and 
0.24, 95% CI = -0.01-0.60 respectively. There was no significant effect of the toolkit 
on the secondary outcomes of self-efficacy, satisfaction and the use of health 
services at six months. 
A recent study looked at the use of a self-care intervention to improve 
confidence in patients with depression and chronic illnesses (114). Two hundred and 
fourteen patients with comorbid depression and poorly controlled diabetes and/or 
coronary heart disease were included in a 12-month study. The outcome measured 
were improvements in knowledge and self-care efficacy. The intervention package 
included: a depression help book, a depression care DVD, a chronic disease 
management booklet and other materials and self-monitoring devices.  Visits were 
scheduled bimonthly or every three weeks with intervention nurses of the regular 
physician in order to create clinical and self-management goals. The aim of these 
visits was to monitor patient progress on depressive symptoms (PHQ-9), medical 
disease control and self-care activities. The results of the study indicated a highly 
significant improvement in confidence for self-care, namely with regards to the ability 
to follow through with medical regimens.  
 
Another study focused on the prevention of depression and anxiety in older 
adults living in 14 residential homes in Amsterdam. One hundred and twenty-nine 
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participants with scores of 8 or higher on the Centre for Epidemiologic Studies 
Depression Scale (CES-D) were randomized either to the intervention group or to 
usual care. The intervention consisted of a self-help module on activity scheduling, a 
program in which patients were given information on how to monitor their mood and 
design a daily activity plan while the usual care included any form of appropriate 
health care. The authors examined the improvement in the level of depressive and 
anxiety symptoms (115). No significant difference was observed between the two 
arms. Only 21% of the participants completed the intervention, with a mean age of 84 
years. They concluded that guided self-help interventions might be difficult to apply in 
very old and vulnerable individuals living in residential homes. 
Also, Johansson and colleagues conducted a 10-week internet-based 
psychodynamic guided self-help intervention for adult depression (116). The objective 
of the study was to improve access to psychological treatment for depression among 
this population. The Mini-international Neuropsychiatric interview was used to 
diagnose depressive symptoms. Participants were randomized to either the treatment 
or control group. The intervention included nine treatment modules based on 
psychodynamic principles with online therapist contact. On the other hand, the active 
control was based on a structured support intervention coupled with psycho-
education and weekly online contact. The result of the study indicated a highly 
significant improvement in depressive symptoms in the intervention group compare to 
the control. The Cohen’s d effect size was estimated at 1.11. 
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Gellatly and Coventry carried out a systematic review of cognitive behavioral 
therapy (CBT) among chronic obstructive pulmonary disease (COPD) patients with 
mild-to-moderate anxiety and depression. Only studies targeting controlled trials 
evaluating the effectiveness of CBT for treating mild-to-moderate anxiety or 
depression in adults with clinically stable COPD were included. The review did not 
find evidence that CBT coupled with exercise training and education could 
significantly reduce anxiety and depressive symptoms among patients with chronic 
obstructive pulmonary disease.(117) 
Finally, Gellatly conducted a systematic review in 2007 on factors that affect 
the effectiveness of self-care interventions in depression treatment. Randomized 
controlled trials on the effectiveness of self-help interventions in the treatment of 
depressive symptoms were identified. Thirty-four studies were selected. In unadjusted 
analyses, factors like unclear allocation concealment, observer-rated outcome 
measures and waiting-list control groups, non-clinical setting recruitment, the 
inclusion of patients with existing depression, contact with a therapist (guided self-
help) and the use of cognitive behavioural therapy techniques were associated with 
greater effectiveness. However, in adjusted analyses, only guided self-help was 
associated with greater effectiveness compared to pure self-help, (p= 0·03). 
2.4  Self-management, depression and eye diseases   
As mentioned in Chapter 1, Section IV, research has indicated an association 
between age-related eye disease and depression, especially in those with (AMD) and 
DR (81, 82, 87). However, no studies have examined the use of self-management 
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interventions on depressive symptoms in this population. A few studies have, though, 
found that brief psychological interventions (greater than 3 hours of professional 
support) can be effective. 
 In a randomized controlled trial, Brody et al examined the 6-month efficacy of 
a brief psychological intervention in reducing depressive symptoms. The sample 
included 32 clinically depressed patients with AMD with a mean age of 81.5 years 
(118). The recruitment was done at the University of California ophthalmology clinics. 
The 15-item Geriatric Depression Scale (GDS-15) questionnaire was used to assess 
depression severity. Patients were included in the study if they had minor or major 
depressive disorder with significant depressive symptoms (≥ to 5 points on the GDS-
15). Participants in the intervention group were given a 12-hour brief psychological 
intervention program comprised of health education and enhancement of problem 
solving skills. The results of the study indicated a statistically significant reduction in 
depressive symptoms in the intervention arm compared to the control arm or waiting 
list, P=.03 (118). 
In a larger study, Brody also examined the 6-month efficacy of the same 12- 
hour brief psychological intervention on outcomes like depressive symptoms, self-
efficacy, and self-reported visual function in 214 patients with AMD. The intervention 
included cognitive and behavioral components, especially information about AMD, 
problem solving skills and a simple exercise program. Participants in the intervention 
group were compared to those on the waiting list. They were all followed-up for a six 
month period (119). Emotional distress was the main outcome. The authors also 
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looked at depression status, visual function and self-efficacy. The findings showed 
less distress in the intervention group compared to the control group, p=. 0008. Also, 
better function and increased self-efficacy were observed, with a p-value of .05 and 
0.006 respectively. In addition, the incidence of clinical depression was significantly 
lower in the intervention group compared to the control group, p=0.05. 
Another study examined the role of problem solving treatment (PST) in 
preventing depression symptoms in people with AMD. Using a randomized controlled 
trial design, patients exposed to problem solving treatment were compared to those 
under usual care. The main outcome measure was the reduction of depression 
incidence and the secondary outcome was the loss of valued activities. Those in the 
intervention arm received six 45 to 60 minute PST sessions at their domicile in an 8-
week period versus usual care in the control arm. The intervention included 
knowledge on problem solving skills such as problem definition, establishing realistic 
goals, identifying solutions and evaluating outcomes. The result of the study indicated 
a reduction in the incidence of depression in the intervention group at 2 months 
compared to the control (OR = 0.43; 95% CI [0.20, 0.95]. However, this reduction was 
attenuated at 6 months and was no longer statistically significant (OR = 0.53, 95% CI 
[0.28, 1.01].(120) 
Another recent study assessed mood, memory, and diabetes mellitus self-
management skills among older African Americans with DR in the US. The diabetes 
mellitus self-management scores was significantly lower among participants with 
depression and memory impairment compared to those without depression or with 
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normal memory, p<.001 and p<0.002 respectively. No self-care interventions have 
previously been tested in patients with diabetic retinopathy to our knowledge.   
 
2.5 Introduction to the project 
This is the first preliminary study that focuses on the use of self-care or self-
management tools in reducing depressive problems in older people with age-related 
eye disease. Various tools were used to collect data necessary to explore this topic. 
These include: 
 The Patient Health Questionnaire (PHQ-9), a 5-minute valid and reliable 9 item 
instrument, was used to measure depressive symptoms.  The scores range 
from 0 to 27,  with cut points of 5, 10, 15 and 20 representing mild, moderate, 
moderately severe, and severe levels of depression, respectively.  The PHQ-9 
has 92% sensitivity and 73% specificity.   
 The Generalized Anxiety Disorder 7 item questionnaire (GAD-7) with good 
sensitivity and specificity was used to evaluate anxiety symptoms. Scores of 5, 
10, and 15 are taken as the cut-off points for mild, moderate and severe 
anxiety, respectively 
 The Blessed Orientation-Memory-Concentration test was used to measure 
cognitive impairment. Scores range from 0 to 28, with a score of 10 of greater 
indicating signs of dementia. 
 The Life Space Assessment questionnaire was used to assess patient mobility. 
Scores range from 0 to 120 with higher scores representing greater mobility. 
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 Self-efficacy was measured using an adapted version of a validated diabetes 
self-care self-efficacy scale  
 Presenting visual acuity in the better eye was taken from the medical record as 
measured by a Snellen chart. 
All potentially eligible patients were screened at the Maisonneuve Rosemont 
ophthalmology clinic using these tools. Additional details concerning the data 
collection process namely the study design, the study population, the intervention, 
the recruitment, the sample size and the statistical methods used as well as the 
results of this study are presented in the next chapter. 
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3.1  Abstract 
Purpose: Depression is a common problem in people with age-related macular 
degeneration (AMD) and diabetic retinopathy (DR). Antidepressants and 
psychotherapy are often underutilized. Our goal was to determine if self-care tools 
plus limited telephone support could reduce depressive symptoms.  
Methods: A single-blind randomized controlled clinical trial was conducted at 
Maisonneuve-Rosemont Hospital in Montreal, Canada. All eligible patients were 
invited to participate in the trial. To be eligible, participants must have had either 
late stage AMD or DR, at least mild depressive symptoms, and visual acuity better 
than 20/200. Half were randomized to the intervention arm and half to delayed 
intervention/usual care. The intervention consisted of large print written and audio 
tools incorporating cognitive-behavioral principles plus three 10-minute telephone 
calls from a coach. Eight-week follow-up data were collected by telephone. The 
primary outcome was the 8-week change in depressive symptoms as measured 
by the Patient Health Questionnaire (PHQ-9).   
Results: Eighty participants were recruited while 10 were lost to follow-up (12.5%) 
giving 70 with complete data. The mean baseline PHQ-9 score was 9.5 (SD=3.9) 
indicating moderate depressive symptoms. The average decrease in PHQ-9 
scores over the 8 weeks was 4.9 (SD=4.2) in the intervention group and 3.2 
(SD=4.6) in the usual care group, a 1.7-point difference (p=0.104). After adjusting 
for baseline imbalances in visual acuity, antidepressant use, and participation in 
psychotherapy, the difference increased from 1.7 to 2.3 and became statistically 
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significant (P=0.037). Sixty percent of those in the intervention group reported 
having used the tools at the end of the study.  
Conclusions: Self-care tools plus telephone coaching led to a small improvement 
in depressive symptoms in patients with age-related eye disease. Additional 
research into the best way to support depressed patients with age-related eye 
disease is necessary. 
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3.2  Introduction 
 Depression is a common problem in people with age-related eye disease as 
29-39% of adults with age-related macular degeneration, Fuchs’ corneal 
dystrophy, or glaucoma experience depressive symptoms (81). Although 
antidepressants and psychotherapy are effective treatments, they remain 
underutilized as 35% of depressed primary care patients have never received any 
depression treatment (121). Among those who have tried treatment, 
antidepressants can cause unpleasant side effects leading to high rates of 
discontinuation (97). Research shows that older adults with depression prefer 
psychotherapy by a 2:1 ratio over antidepressants (98). Yet, psychotherapy in the 
private healthcare system is expensive, wait times in the public system can be 
long (122), and there is still a stigma towards psychotherapy in some populations 
(123). Therefore, the investigation of alternative treatments for depression is 
important.   
 There is already evidence that brief psychological interventions can 
decrease depressive symptoms or reduce the incidence of depressive symptoms 
in patients with AMD, at least in the short-term (119, 120, 124). Brief psychological 
interventions typically take between 6 and 10 hours of time and are delivered by a 
health professional either in a group format or one-on-one in the home. These 
interventions are very promising, yet the time needed to deliver the intervention 
increases its cost and decreases its feasibility to be widely offered as a routine 
part of vision care. 
 Therefore, we decided to investigate whether depression self-care tools, 
which are defined as requiring less than 3 hours of professional support (125), 
27 
 
could decrease depressive symptoms in patients with age-related eye disease. 
Self-care (sometimes referred to as self-management) interventions are advocated 
as an essential part of chronic disease care (106). These interventions typically 
include components on behavioral activation and problem solving (106). Meta-
analyses indicate that depression self-care interventions can be useful although 
most studies have been carried out in younger, non-clinical, self-referred 
populations (125). No studies to our knowledge have examined self-care 
interventions and their effect on depressive symptoms in patients with age-related 
eye disease.  
 Our hypothesis was that self-care tools plus limited telephone coach 
support would decrease depressive symptoms and anxiety while increasing life 
space and self-efficacy in a population with age-related eye disease. We chose to 
conduct this trial in patients with (AMD) or (DR) since the prevalence of depression 
in these groups is high (81, 126) and since both groups experience losses in visual 
acuity. 
3.3  Methods 
3.3.1 Study Population 
 Participants were recruited from the retinal clinics of Maisonneuve-
Rosemont Hospital in Montreal, Canada from November 2014 through December 
2015. Eligibility criteria included age >50, a clinical diagnosis of late stage age-
related macular degeneration or any stage of diabetic retinopathy, a score of 5 or 
greater on the Patient Health Questionnaire 9-item depression scale indicating at 
least mild depressive symptoms(127), visual acuity in the better eye better than 
20/200, a score of less than 10 on the Blessed-Orientation-Memory-Concentration 
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(BOMC) test indicating adequate cognition to participate in the study (128), and a 
signed informed consent form. An exclusion criterion was if the person was 
already in cognitive behavioral therapy (CBT).  All participants were paid $40.  The 
ethics board of Maisonneuve-Rosemont Hospital approved the study and the 
tenets of the Declaration of Helsinki were observed. 
3.3.2 Recruitment 
 All potentially eligible patients were approached in the waiting room and 
informed about the study (see flow chart, list of figures). Those interested were 
then asked to sign the consent form and were assessed for eligibility. 
3.3.3 Study Design 
 An 8-week single-blind randomized controlled clinical trial was conducted.  
Participants were randomized to the intervention arm or the usual care arm. The 
randomization sequence was obtained using a random number generator website 
with a block size of four. Assignments were individually inserted into ordered 
sealed envelopes that were opened in front of the participant. Those in the 
intervention group received the self-care tool intervention plus up to three 
coaching phone calls. Both groups were called 8 weeks after recruitment by 
telephone by an interviewer masked to treatment assignment and were given a 
follow-up questionnaire. After the follow-up questionnaire was completed, the 
usual care group received the self-care tools by mail plus one coach call. The 
CONSORT guidelines for non-pharmacologic interventions were followed (129). 
The trial was registered at clinicaltrials.gov.  
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3.3.4 Intervention 
 The tools were used previously in a clinical trial among middle-aged and 
older primary care patients with chronic physical conditions but without vision loss 
(113). To determine if the tools needed modification for patients with vision loss, 
they were evaluated in July 2014 in a pilot study of 10 people with low vision and a 
history of depression. The general consensus from this pilot study was that the 
tools were useful but that the print should be further enlarged from 14-point to 18-
point font and the contrast should be further enhanced. These modifications were 
made prior to study inception. 
 The toolkit consisted of a 3-ring binder notebook filled with written tools 
using 18-point font as well as audio tools. Two of the tools incorporated cognitive-
behavioral therapy principles: the Antidepressant Skills Workbook (written and 
audio versions) (130) and a Mood Monitoring tool.  These two tools along with a 
DVD on depression were the three core tools of the toolkit. The other tools were 
only recommended to those the coach thought would benefit: a relaxation CD, 
information on low vision resources, information on medication misuse and 
emotional eating, and information for family members on how to be supportive. In 
addition, participants were offered support in the form of three 10-minute phone 
calls from a trained coach to encourage use of the tools and answer questions. 
These calls were recorded to ensure the fidelity of the intervention. Less frequent 
phone calls were also an option, if preferred. The coach, who was a former nurse, 
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underwent 15 hours of training by an experienced psychotherapist with experience 
in self-care tools. The usual care group received the toolkit after the follow-up 
interview and at that time received one coach call.  
3.3.5 Data Collection 
 Data were collected at both baseline and the 8-week follow-up. The 
interviewers were masked to the treatment assignment of the participant. 
Depressive symptoms were measured with the PHQ-9 instrument (92% sensitivity, 
73% specificity)(127). This 9-item instrument is a valid and reliable measure of 
depressive symptoms, with cut points of 5, 10, 15 and 20 representing mild, 
moderate, moderately severe, and severe levels of severity, respectively. The 
GAD-7 was used to evaluate anxiety symptoms (131). This 7 item questionnaire 
has demonstrated very good sensitivity (89%) and good specificity (82%) (131).  
Life space, which measures the spatial extent of a person over the last 
month, was measured using the Life Space Assessment (LSA) (132). This was 
particularly measured as depressive people tend to isolate themselves from 
others. As mentioned in the literature section, Limited mobility or a low spatial 
extent could be associated with depression. The LSA measures the frequency of 
going to 5 life space levels (places inside house but outside bedroom, places just 
outside home, places in neighborhood, places outside neighborhood but within 
city, places outside city) and whether technical or personal assistance was 
required. Scores range from 0 to 120 with higher scores representing greater life 
space. This tool has been found to be valid and reliable (132). Self-efficacy with 
regard to depression self-care was measured using an adapted version of a 
validated diabetes self-care self-efficacy scale (133). Four statements were read 
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(e.g. I am able to carry out daily activities that keep my mood positive). 
Participants had to rate their level of agreement with responses ranging from 
strongly disagree to strongly agree on a 4 point scale. Cognitive Impairment was 
measured with the Blessed Orientation-Memory-Concentration test (BOMC)(128).  
Patients with a score of 10 or greater, having signs of dementia or 
cognitive impairment were excluded from the study while those with normal 
cognition (scores 0-5) and those with mild cognitive impairment (scores of 5-9) 
were included. Participants were asked about physician diagnoses of 13 chronic 
medical conditions (e.g. arthritis, diabetes, and stroke) including depression and 
about prescription medications taken for low mood or anxiety. Demographic 
information on age, gender, race, and education were collected. Presenting visual 
acuity in the better eye was taken from the medical record as measured by a 
Snellen chart. Scores were then converted to the log of the minimum angle of 
resolution (logMAR). Any adverse events that happened during the study period 
were recorded. At the end of the follow-up interview, masking was broken and 
participants were asked about the tools that they used during the follow-up period.  
 Additional information was recorded by the coach. The coach recorded 
information about the date of the call, the needs of the participant, and the tools 
that were used and recommended for next time. 
 Efforts were made to maximize follow-up and minimize missing data. The 
coach was instructed to encourage participants to allow the follow-up interviewer 
to contact them even if participants did not want to engage in coaching or use the 
toolkit. 
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3.3.6 Primary and Secondary Outcomes 
 The primary outcome was the 8-week change in PHQ-9 depressive 
symptoms. Secondary outcomes included 8-week changes in life space, anxiety, 
and self-efficacy.   
3.3.7 Statistical Analysis and Power 
 Baseline characteristics were compared between the intervention and usual 
care groups to ensure that the randomization process worked. Clinically significant 
imbalances were noted. The difference between the baseline and the follow-up 
value was calculated for each outcome with positive values indicating an 
improvement and negative values indicating a worsening.  Student’s t-tests were 
used to determine whether the intervention group had greater changes in the 
outcomes than the usual care group. Linear regression was used to adjust for any 
baseline variables that had clinically important imbalances between the 
intervention and usual care groups.  
Interaction was assessed to examine whether the intervention only worked in 
certain subgroups, e.g. AMD versus DR status, those with greater education, 
milder depressive symptoms, better vision, better cognition, or more self-efficacy. 
Interaction terms were tested for statistical significance in linear regression 
models. Statistically significant interactions were further examined in stratified 
analyses. For the primary outcome, intention-to-treat analyses using multiple 
imputations to replace missing outcome data for those lost to follow-up and 
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complete case analyses were done. For the secondary outcomes, only complete 
case analysis was done. Analyses were done using Stata Version 11 (College 
Station, Texas).   
 With at least 35 people in each group and an average standard deviation of 
the change in PHQ-9 scores of 4.4, we had 80% power to detect a 3-point 
difference in the 8-week change scores between the intervention and usual care 
groups. An individual change of 5 or more on the PHQ-9 is considered clearly 
clinically significant (134, 135) while a change from 2.5-4 is considered to be 
borderline clinically significant (134, 135).  
3.4 Results 
 The recruitment and retention rates are described in Figure 1. We reviewed 
2,986 charts to determine phase 1 eligibility (diagnosis, age, and visual acuity). Of 
those with phase 1 eligibility (n=1,223), 258 people (21%) agreed to be evaluated 
for phase 2 eligibility (i.e. PHQ-9, BOMC) with 80 people meeting all eligibility 
criteria. Eighty people were randomized in block sizes of 4, which led to 39 in the 
usual care group and 41 in the intervention group. We lost 10 people to follow-up, 
6 in the intervention group and 4 in the usual care group giving 35 in each group.  
Those lost to follow-up were fairly similar to those who completed the study in 
terms of age, visual acuity, education, and baseline depression and anxiety scores 
(P>0.10) (data not shown).  
 The mean age of the sample was 76 years old (SD=12) while 38% were 
men. Fifty-five percent of the sample had AMD while 45% had DR. The mean 
logMAR visual acuity in the better eye was 0.37 (SD=0.2) (20/50 Snellen acuity) 
and the mean PHQ-9 score was 9.5 (SD=3.9). Despite everyone in our sample 
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having at least mild depressive symptoms, very few people were receiving 
treatment for depression. Overall, 4% were involved in non-CBT psychotherapy 
while 20% were taking antidepressants. The baseline characteristics of the two 
treatment groups were fairly similar (Table 1). There were some imbalances, 
though, in visual acuity, use of antidepressants, and use of psychotherapy. These 
variables were chosen to include in regression models given their imbalance and 
their potential importance to depression levels.     
 Both the intervention group and the usual care group had a decrease in 
depressive symptoms over the 8-week follow-up period although the decrease in 
the intervention group was slightly greater (mean 4.9, SD=4.2) than the usual care 
group (mean 3.2, SD=4.6) (Table 2) giving an overall difference of 1.7 points 
between the two groups. This difference was not statistically significant (p=0.104). 
However, when we adjusted for visual acuity, antidepressant use, and 
psychotherapy use, the difference increased to 2.3 and became statistically 
significant (p=0.037).  Analyses using multiple imputation to replace missing 
outcome values for the 10 people who were lost-to-follow-up gave similar results 
(P=0.134 for the unadjusted results and P=0.030 for the adjusted results).   The 
intervention had minimal effects on the secondary outcomes (p>0.10 for both 
unadjusted and adjusted results) (Table 2). No statistically significant interactions 
were detected with level of depressive symptoms, cognitive impairment, 
educational level, visual acuity, self-efficacy, or eye disease diagnosis.  
 The intervention did not motivate people to initiate standard therapy for 
depression over the 8-week follow-up period. Three people (4%) reported currently 
receiving non-CBT therapy or counseling at follow-up, two of whom started it 
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during follow-up. One was in the intervention group and one was in the usual care 
group. Fourteen people (20%) reported currently taking medications for emotional 
or mood problems at follow-up. Three of the 14 initiated these medications after 
the start of our study, one in the intervention group and two in the control group. 
 To better understand why our intervention did not have a greater effect, we 
examined the frequency of tool use reported to the coach by the number of coach 
contacts (Table 3). Of the 33 people who had at least 1 coach call, 21% had one 
coach call, 27% had two, and 52% had three. Overall, 70% reported using any of 
the three core tools to the coach. This differed by the number of coach calls as 
only 29% reported using the core tools if they had only one coach call whereas 
over 78% reported using any core tools if they had two or three coach calls. The 
report of tool use was a bit lower when reported to the follow-up interviewer at the 
end of the study as at that time only 60% reported using any tools.  
Reasons given to either the coach or the follow-up interviewer for not 
using the tools including having difficulty with vision (40%), being too busy (50%), 
not interested (20%), not identifying with a label of depression (10%), and 
technical problems with the audio tools (20%).  Those in the intervention group 
who reported using a tool did not have a significantly different change in 
depressive symptoms compared to those in the intervention group who did not use 
a tool or those in the usual care group (p=0.265). No variables were statistically 
significantly associated with tool use among those in the intervention group 
although those who used the tools had three more years of education on average 
than those who did not use the tools (12 years versus 9 years, p=0.064) and 
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women were much more likely to report using the tools than men (70% versus 
33%, p=0.071).  Further studies should focus on the low use of these tools. 
3.5  Discussion 
The aim of this study was to evaluate whether self-care tools plus minimal 
telephone coaching (<3 hours professional support), could alleviate depressive 
symptoms in patient with age-related eye disease. This is the first study 
addressing the high rates of depressive symptoms in this population. Our 
intervention had a small effect by reducing depressive symptoms more than usual 
care by 2.3 points, on average. The minimum clinically important difference on the 
PHQ-9 is 5, although changes of 2.5-4 are considered to have borderline clinical 
significance (134, 135). There was no effect of the intervention on our secondary 
outcomes of anxiety, life space, or self-efficacy.  
 Depressive symptoms decreased over the 8-week period in both groups: by 
3.2 points in the usual care group and 4.9 points in the intervention group. The 
decrease in the usual care group may be due to the natural history of depression 
or to regression to the mean, a statistical phenomenon that occurs when multiple 
measurements are taken on a single person and a threshold is used to determine 
eligibility for the study (136). Participants were only eligible if they had a score of at 
least 5 on the PHQ-9 so on average; we expected scores to decrease over time. 
The use of a randomized comparison group allowed us to determine if our 
intervention had an effect beyond this expected decrease.  
 To understand why the intervention did not have a greater effect, we 
examined the frequency of tool use as reported to the coach and the follow-up 
interviewer. Tool use as reported to the coach was slightly higher (70%) than that 
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reported to the follow-up interviewer at the end of the study (60%). This could 
either be because participants had forgotten that they had used the tools earlier in 
the study or that some had falsely reported using the tools to the coach in an 
attempt to give a socially desirable answer. The reasons for not using the tools 
(e.g. too busy, difficulty with vision) may indicate that the tools were not sufficiently 
user-friendly for this population despite our attempts to enlarge the font and to 
provide audio versions of the tools. Certainly, to be effective, self-care tools 
require self-motivation, a willingness to be introspective, and a commitment to do 
the recommended exercises, and those may have been unreasonable 
expectations for much of this population as only 49% of those in the intervention 
group completed all three coach calls and 10 people (12.5%) were lost to follow-up 
over the 8 weeks.   
 We know from the literature that self-care tools can be effective for 
depression but many of the studies with positive results were done in self-referred, 
younger populations rather than older, clinical populations approached in a 
systematic way (125). Given our modest results, it may be that greater coaching 
support is required or that a more intensive intervention, such as the brief 
psychological interventions found effective previously, are better approaches in 
older adults with vision loss.  Rovner et al conducted problem-solving therapy in 
patients’ homes (120) while Brody et al conducted group self-management 
sessions at a university (119). Both approaches led to clinically significant 
reductions in depressive symptoms or in the incidence of depression. The 
disadvantages of these approaches are that they cost more to implement on a 
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large scale and they require either an ability to travel frequently to the hospital for 
group sessions or a willingness to invite a person into the home.  
 
 Strengths of this study included the randomized controlled clinical trial 
design, the blinded nature of the data collection, and the novel examination of self-
care tools in a population of people with age-related eye disease. We had more 
than enough statistical power to detect an effect that was clinically significant 
(PHQ-9 change of >=5) or borderline clinically significant (PHQ-9 change of 2.5-4). 
A limitation is that 12.5% were lost-to-follow-up. However, our results were 
unchanged when we used multiple imputations to replace missing values. In 
addition, the 8-week follow-up may have been too short to see an effect and 
perhaps this population of older adults with visual impairment and about 1/5 with 
mild cognitive impairment would have benefited from more than three coaching 
calls.  
In conclusion, our intervention had a small benefit on depressive 
symptoms in patients with age-related eye disease. Additional research into the 
best way to support depressed patients with age-related eye disease is necessary 
for patients to optimally participate in their vision treatment regimen.  
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4 Figure1: Recruitment and retention flow chart 
  
Assessed for Phase 2 
eligibility (n=258) 
Excluded (n=178) 
   Not meeting inclusion 
criteria (n=176) 
   Declined to participate 
(n=2) 
 
Analyzed (n=35) 
Lost to follow-up (n=6) 
Withdrawal (n=4) 
□ Unable to contact (n=2) 
  
 
Allocated to receive self-care tools plus 
coaching (n=41) 
 
 Lost to follow-up (n=4) 
 Withdrawal (n=4) 
Allocated to receive usual care 
(n=39) 
 
 
Analyzed (n=35) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=80) 
Enrollment 
Screening 
Phase 1 eligibility (n=1,223) 
   Declined to participate 
(n=965) 
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5 Table 1:  Baseline characteristics of participants by treatment 
assignment 
 Self-Care Intervention 
n=41 
Mean (SD) or %* 
Usual Care 
n=39 
Mean (SD) or %* 
Age, Years 75.1 (11.1) 73.0 (10.8) 
Gender 
    Male 
    Female 
 
34% 
66% 
 
41% 
59% 
Education, Years 10.9 (4.1) 11.3 (3.8) 
Median Visual Acuity 
(IQR), logMAR 
0.36 (0.18) 0.30 (0.24) 
Diagnosis 
     AMD 
     DR 
 
54% 
46% 
 
56% 
44% 
No. of Co-morbidities 4.0 (2.2) 3.6 (2.1) 
Mild Cognitive 
Impairment 
17% 23% 
Using Antidepressants 9% 23% 
Undergoing 
Psychotherapy (but not 
CBT) 
7% 0% 
PHQ-9 Depression 9.5 (3.7) 9.5 (4.2) 
GAD7 Anxiety 6.0 (5.1) 5.8 (5.1) 
Life Space 47.2 (26.9) 44.6 (24.0) 
Self-Efficacy 7.7 (1.8) 8.1 (2.0) 
*Unless otherwise specified 
Abbreviations:  IQR=interquartile range; logMAR=log minimum angle of resolution; 
CBT=cognitive behavioral therapy; AMD=age-related macular degeneration; 
DR=diabetic retinopathy 
*Visual acuity, use of antidepressant and psychotherapy were not balanced 
between the groups 
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6 Table 2:  Eight-week change values* by treatment assignment 
 Intervention   Usual Care     
Outcome Baseline 
Mean (SD) 
Follow-up 
Mean (SD) 
Change* 
Mean (SD) 
Baseline 
Mean (SD) 
Follow-up 
Mean (SD) 
Change* 
Mean (SD) 
P-
value† 
P-
value‡ 
Depressive 
Symptoms 
9.1 (3.5) 4.2 (4.0) 4.9 (4.2) 9.2 (4.2) 6.0 (4.3) 3.2 (4.6) 0.104 0.037 
Anxiety 
Symptoms 
6.4 (5.3) 3.2 (3.5) 3.2 (5.6) 5.5 (5.1) 3.8 (3.9) 1.7 (5.0) 0.245 0.205 
Life Space 46.3 (28.1) 44.1 (22.2) -2.2 (24.3) 45.0 (23.7) 41.7 (19.9) -3.9 (19.6) 0.751 0.653 
Self-Efficacy 7.7 (1.7) 8.3 (1.7) 0.5 (2.2) 7.9 (2.1) 8.1 (1.3) 0.2 (2.2) 0.532 0.568 
 
*Positive change scores indicate improvements over the 8 week period.  Negative change scores indicate a worsening. 
† Student’s t test comparing the change in the intervention group to the change in the usual care group.  
‡ Linear regression model adjusting for visual acuity, use of antidepressants, and use of psychotherapy 
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7 Table 3: Use of tools by those in the intervention group according 
to coach log (n=33*) 
Tool Used 1 coach  
contact 
n=7 
2 coach 
contacts 
n=9 
3 coach 
contacts 
n=17 
Antidepressant 
Skills Workbook 
29% 78% 71% 
DVD on Depression 0% 33% 24% 
Relaxation CD 0% 44% 24% 
At Least One Core 
Tool Used 
29% 78% 82% 
Additional 
Resources 
0% 11% 6% 
Medication Misuse 0% 0% 0% 
Emotional Eating 0% 22% 12% 
Family Support 
Booklet 
0% 0% 0% 
 
*Two people did not receive any coach calls 
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Chapter 4: Discussion  
4.1  Self-care intervention for depression in old population with aged 
related eye diseases 
 
This is the first study to assess the use of self-care tools to reduce depressive 
symptoms among older adults with limited vision. We hypothesised that the tools 
could reduce depressive and anxiety symptoms or possibly increase self-efficacy and 
life space in older adults with age-related macular degeneration or diabetic 
retinopathy. A randomized controlled trial was conducted to assess this hypothesis. 
The results of the study showed that self-care tools, with limited phone support could 
alleviate depressive symptoms among these populations although the effect was 
small.  
It is however important to point out the percentage of participants who reported using 
the tools was lower than expected, only 60%. Among the reasons cited for not-using 
the intervention material, a lack of motivation, visual difficulties with the material, a 
resistance to being labeled “depressed”, and technical difficulties were often cited. 
Although evidence of the efficacy of self-care tools on depression has largely been 
documented in younger, non-clinical and self-referred populations, our study 
participants were relatively older with limited vision. Moreover, the study sample was 
not self-selected as seen in previous studies: all willing individuals were invited to 
participate. This may be why the effect of our intervention was smaller than that found 
in previous studies.  Furthermore, there were no effects of the intervention on anxiety, 
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life space, or self-efficacy.  Although we hypothesized that the Antidepressant Skills 
Workbook would have an effect on all the outcomes, perhaps a longer follow-up 
period was necessary to see an impact of the tools on these secondary outcomes or 
perhaps the intervention did not target these secondary outcomes sufficiently.  
Additional studies are needed to further understand the potential of self-care tools to 
reduce depressive symptoms and improve the quality of life among older populations 
with age-related eye diseases. It’s necessary to identify new strategies in order to 
make the tools more appealing and user friendly to this population. Additional focus 
groups should be held among those with vision loss so as to determine the best way 
to develop and carry out this intervention among this population. 
4.2  Strength and limits of the study 
We conducted an 8 week study to evaluate the intervention. The duration of the study 
may have been too short for this population to see a larger, more clinically significant 
effect. However, we thought that any effect would be strongest in the first few months 
and would then taper off after the novelty of the tools wore off.  Furthermore, the 
funding available was not sufficient to cover a longer study period.  
Also, the single blind nature of the intervention might have introduced some bias in 
the results. The participants knew which group they were assigned to, either the 
intervention or the control group. Thus, they might have reported information 
differently at follow-up depending on their assigned group. For example, those who 
received the intervention might have reported fewer depressive symptoms because 
they felt it was more socially desirable to indicate that the intervention had been 
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helpful. A double-blinded study would have been more rigorous.  However, we 
struggled to imagine an intervention for the control group that would not have any 
effect on depressive symptoms and that we could develop in the short time frame we 
had available to do this study.  Future research should consider developing a placebo 
that will not affect depressive symptoms in order to carry out a double blind study in 
this setting. 
In the sample size calculation, we assumed that about 15% of our participants would 
be lost to follow up, given the age of the population and their vulnerability. At the end 
of the follow up, 12.5% decided to drop out of the study or were simply not reachable. 
Missing data are always a concern for bias.  However, the descriptive statistics 
showed similarities in the characteristics of those who remained in the study 
compared to those lost to follow up. Also, we performed multiple imputation, the gold 
standard way of dealing with missing data, to deal with the losses to follow up. The 
results of the study did not change when taking the losses to follow up into account. 
With regards to the strengths of the study, this is the first study to examine the use of 
self-care tools to alleviate or reduce depressive symptoms among older adults with 
age- related eye disease.  To our knowledge, no study has been done in this regard, 
especially in patients with AMD or DR, who are most at risk for depressive symptoms.  
In addition, we used a randomized controlled trial design, which is the gold standard 
study design for evaluating efficacy. Moreover, all eligible participants were 
approached about participation in the study instead of just relying on self-referred 
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patients as many other self-care studies have done.  This increases the 
generalizability of our results.  
 
4.3 Clinical implications and future research 
 This study was the first step in examining the short-term efficacy of self-care tools in 
reducing depressive symptoms in this population. The results indicated that these 
tools could be useful but that the effect needs to be maximized in order to be more 
clinically significant. Further research including a longer follow up period and 
strategies to maximize the effect such as more coaching calls or alternative ways of 
delivering the intervention are needed.  If the efficacy of self-care tools to treat 
depressive symptoms is confirmed, this could be a significant step in the treatment of 
depression among older adults with age-related eye diseases.  Identifying alternative 
treatment options that are accessible and less costly could be a big advancement in 
the treatment of depression. The identification of such a treatment might not only 
contribute to the reduction of the burden of the disease as a whole but increase 
adherence to the visual treatment regimen, reduce vision loss, and improve patient 
quality of life. Such tools could be integrated into the low vision rehabilitation program 
or be offered in ophthalmology and optometry clinics. 
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Appendices  
1. Patient Baseline Interview 
Instructions to interviewer: 
Please note that only text in bold should be read to patients. Additional questions that may 
be needed for probing are italicized.  
For any question where a preset response was not selected, choose the “other code” that 
applies (N.B. these codes are to be used as little as possible; before using them, try to 
probing respondent more for an answer): 
 Not applicable (NA): 77 
 Don’t know (DK): 88 
 Refused (R): 9 
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Thank you for agreeing to this interview. All the information you provide will be kept 
entirely confidential. If you feel uncomfortable answering any of the questions, let me 
know and we can skip it. To ensure that we have enough time to get through all the 
questions, please use only the answer choices provided.  
ISURG1: INJECTION TODAY?       
1.  YES      2.  NO 
 
Section A: Medications 
MED1: First, let’s talk about your prescribed medications.   
Must be current medications, i.e. taken during the last week. 
List the medications in the following chart. If patient has a print-out list and allows you to 
keep it, then you do not need to list the medications here. 
 
*If NONE, skip to Section C* 
 
Name 
# of times/day or 
# of times/week 
1a.  
1b.  
1c.  
1d.  
1e.   
1f.   
1g.   
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Section B: Medications and Adherence 
 
MED 2. Considering all your prescription medicines… 
 
MED2a.   During the past week, did you ever forget to take any of these medicines? 
0 No 
1 Yes  
88 DK 
Refused 
 
MED2b. During the past week, were you careless at times about taking any of these 
medicines? 
Were there times when you couldn’t be bothered to take them? 
0 No 
1 Yes 
88 DK 
Refused 
 
MED2c. During the past week, if you felt better did you sometimes not take or entirely 
stop taking any of these medicines? 
0 No 
1 Yes  
88 DK 
Refused 
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MED2d.  During the past week, if you felt worse when you took any of these 
medicines, did you stop taking them? 
0 No 
1 Yes  
88 DK 
99 Refused 
 
 
Section C: General Health Status 
 
The next question asks for your view about your health.  
 
GHS.  In general, would you say your health is… 
0 excellent? 
1 very good? 
2 good? 
3 fair? 
4 poor? 
88 DK 
Refused 
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Section D: GAD-7 
 
Over the last 2 weeks, how often have you been bothered by any of the following 
problems? For each item, please tell me if you have not been bothered at all, been 
bothered for several days, been bothered more than half the days, or been bothered 
nearly every day. 
Remind respondents of the choices when necessary 
If patient says “1 day” mark as “several days”. 
 
 Problem Not at 
all 
Several 
days  
More 
than 
half the 
days 
Nearly 
every 
day 
Other: 
88 DK 
99 R 
1 Feeling nervous, anxious, or on 
edge 
0 1 2 3  
2 Not being able to stop or control 
worrying 
0 1 2 3  
3 Worrying too much about 
different things 
0 1 2 3  
4 Trouble relaxing 0 1 2 3  
5 Being so restless that it is hard to 
sit still 
0 1 2 3  
6 Becoming easily annoyed or 
irritable 
0 1 2 3  
7 Feeling afraid as if something 
awful might happen 
0 1 2 3  
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Section E: Everyday Activities 
Now I would like to ask you about your daily activities. Please tell me how many times 
you may have engaged in each activity in the past week. 
 In the past week, how many times did you… # of times 
 
Other: 
99 R 
1 Visit with family, relatives, friends, or neighbours 
in person? 
  
2 Have a telephone conversation with family, 
relatives, friends, or neighbours? 
 
 
 
3 Contact family, relatives, friends, or neighbours 
through electronic means other than telephone? 
For example, email, text messaging, or Facebook.  
  
4 Attend a religious service, such as church or 
synagogue or mosque? 
 
 
 
5 Participate in a social or recreational group 
activity? 
  
6 Take a day trip or overnight trip?   
7 Go to a concert, play, or art exhibition?   
 
 How many DAYS (not “times”!) in the past week, 
did you… 
# of DAYS 
 
Other: 
99 R 
8 Spend time on hobbies such as collecting or 
handiwork? 
  
9 Spend time reading, writing (including time on the 
computer but not work-related), or listening to 
music? 
  
10 Do light housework or gardening?   
11 Do heavy housework or yard work?   
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Do you currently do volunteer work? 
0 No  ]go to next section 
1 Yes  
88 DK ]go to next section 
 ]go to next section 
 
12a. How many days in the last week did you engage in volunteer work? 
________ days 
88 DK   
99 R   
 
13.  Do you ever use the Internet, for example, checking your email, finding 
information? 
0 No ]  Go to Section G 
1 Yes 
R ]  Go to Section G 
 
13a. how often do you use the Internet in a typical month? 
1   At least once a day  
2   At least once a week (but not every day)  
3   At least once a month (but not every week)  
4   Less than once a month  
88 DK 
99 R 
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Section F: Smoking  
 
I would like to ask you some questions about smoking. 
 
SMK1.  Have you ever smoked (that includes cigars, pipes or cigarettes)? 
0 No    go to next section 
1 Yes 
99 Refused  go to next section 
 
SMK2.  Do you currently smoke any of these? 
0 No   go to next section 
1 Yes  
99 Refused  go to next section 
 
SMK3.  Which ones? 
Multiple answers permitted, probe to record all possible answers.  
0 cigarettes   
1 pipes    go to next section 
2 cigars  go to next section 
3 other   go to next section 
99 refused  go to next section 
 
SMK4.  How many cigarettes a day did you smoke during the last week? 
____ cigarettes / day 
99 Refused 
88 Don’t know 
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Section G:  Life Space Questionnaire 
LS1. During the past 4 weeks but not including today, have you been to another room of 
your home besides the room where you sleep? 
0.  No (SKIP TO QUESTION 2) 
1.  Yes   
2.  Refuse (SKIP TO QUESTION 2) 
 
LS1a.  If yes, how often did you go to another room besides the room where you sleep? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
 
LS1b.  Did you use technical aids or equipment to get there (for example a cane or a 
walker)? 
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS1c.  Did you need help from another person to get there?  
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
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LS2. During the past 4 weeks, have you been to an area outside your home such as your 
porch, deck, patio, hallway (of an apartment building) or garage in your own yard, or 
driveway? 
0.  No (SKIP TO QUESTION 3) 
1.  Yes   
2.  Refuse (SKIP TO QUESTION 3) 
 
LS2a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
LS2b.  Did you use technical aids or equipment to get there (for example a cane or a 
walker)? 
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS2c.  Did you need help from another person to get there?  
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS3. During the past 4 weeks, have you been to places in your neighbourhood, other than 
your own yard or apartment building? 
0.  No (SKIP TO QUESTION 4) 
1.  Yes   
2.  Refuse (SKIP TO QUESTION 4) 
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LS3a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
2. 1-3 days / week 
3. 4-6 days / week  
4. Daily  
 
LS3b.  Did you use technical aids or equipment to get there (for example a cane or a 
walker)? 
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS3c.  Did you need help from another person to get there?  
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS4. During the past 4 weeks, have you been to places outside your own neighbourhood but 
within your town? 
0.  No (SKIP TO QUESTION 5) 
1.  Yes   
2.  Refuse (SKIP TO QUESTION 5) 
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LS4a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
2. 1-3 days / week 
3. 4-6 days / week  
4. Daily  
 
LS4b.  Did you use technical aids or equipment to get there (for example a cane or a 
walker)? 
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS4c.  Did you need help from another person …?  
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS5. During the past 4 weeks, have you been to places outside your town? 
0.  No (SKIP TO NEXT SECTION) 
1.  Yes   
2.  Refuse (SKIP TO NEXT SECTION) 
 
LS5a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
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LS5b.  Did you use technical aids or equipment to get there (for example a cane or a 
walker)? 
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
 
LS5c.  Did you need help from another person to get there?  
0.   No 
1.  Yes   
2.  Refuse or Don’t Know 
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Section H:  Self-Efficacy 
 
I am going to read to you some statements that people sometimes make when they talk 
about their mood.  For each statement, please indicate how much you agree or 
disagree with each statement as it applies to you personally.  
 
Repeat choices whenever necessary. 
 
If respondent answers don’t know, probe more: 
You don’t know because you don’t understand?Because you’re not sure? 
Try to narrow down what it is in the statement that makes the patient not know. 
 
 Disagree 
strongly 
Disagree Agree Agree 
strongly 
Don’t 
Know 
Refuse 
 I am able to carry out 
daily activities that can 
keep my mood positive 
0 1 2 3 88 99 
I feel confident that I can 
recognize situations that 
will bring my mood down 
0 1 2 3 88 99 
I feel able to meet the 
challenges of learning and 
practicing new skills to 
control my mood 
0 1 2 3 88 99 
I am capable of stopping 
my mood from becoming 
negative. 
0 1 2 3 88 99 
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Section I:  Social Networks 
FAMILY/PARTNER: Considering the people to whom you are related either by birth 
or marriage/partnership . . . 
 
LUB1. How many relatives do you see or hear from at least once a month?  
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = nine or 
more 
 
LUB2. How many relatives do you feel close to such that you could call on them for 
help? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = nine or 
more 
 
LUB3. How many relatives do you feel at ease with that you can talk about private 
matters? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = nine or 
more 
 
 
FRIENDSHIPS: Considering all of your friends including those who live in your 
neighborhood.  
 
LUB4. How many of your friends do you see or hear from at least once a month? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = nine or 
more 
 
LUB5. How many friends do you feel close to such that you could call on them for 
help? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = nine or 
more 
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LUB6. How many friends do you feel at ease with that you can talk about private 
matters? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = nine or 
more 
 
Section J:  Sociodemographics 
Next, I would like to ask some general questions about you. 
SOC1:  What is your marital status?  
0  married? 
1  living common-law? 
2 widowed? 
3 separated? 
4 divorced? 
5 single, never married? 
99 Refused 
 
SOC2:  How many years of education did you complete?  ________ 
99 Refused 
 
SOC3: Gender (OBSERVE) 
     0    Male 
     1      Female 
  
SOC4:  Race (OBSERVE) 
       0 White 
       1 Noir 
       2 Other (Specify) 
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SOC5:  Address:     
____________________________________________ 
 
 _____________________________________________ 
 
____________________________________________ 
 
SOC6: Telephone Number Where We Can Reach You Over Next 2 Months 
  
   ____________________________________________ 
 
 
SOC7: Secondary Telephone Number (Optional) 
  
   ____________________________________________ 
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Section K:  Health Conditions 
 
HEALTH1:  Has a physician ever told you that you have arthritis? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH2:  Has a physician ever told you that you have asthma? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH3:  Has a physician ever told you that you have emphysema or chronic obstructive 
pulmonary disorder? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH4:  Has a physician ever told you that you have diabetes? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH5:  Has a physician ever told you that you have hypertension or high blood 
pressure? 
  0.  NO 
  1.  YES 
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  2.  DON`T KNOW OR REFUSE 
 
HEALTH6:  Has a physician ever told you that you have peripheral artery disease or 
intermittent claudication? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH7:  Has a physician ever told you that you have heart disease (angina, 
atherosclerosis, arrhythmia, congestive heart failure, heart attack, coronary artery disease, 
atrial fibrillation, etc.)? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH8:  Has a physician ever told you that you had a stroke? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
HEALTH9:  Has a physician ever told you that you have Parkinson’s disease? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
HEALTH10:  Has a physician ever told you that you have impaired hearing? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
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HEALTH11:  Has a physician ever told you that you have depression? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH12:  Has a physician ever told you that you have a back problem? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
HEALTH13:  Has a physician ever told you that you fractured your hip? 
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
LV1:  Are you aware of the existence of low vision rehabilitation agencies in Montreal like 
CNIB, INLB, or MAB-Mackay? 
0.  NO     (END OF QUESTIONNAIRE) 
  1.  YES         
  2.  DON`T KNOW OR REFUSE      (END OF QUESTIONNAIRE) 
LV2:  Have you ever visited one of these agencies?   
  0.  NO 
  1.  YES 
  2.  DON`T KNOW OR REFUSE 
 
END OF QUESTIONNAIRE FOR PARTICIPANT 
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Section L: Vision and Eye Disease 
 
INTERVIEWER:  Please measure visual acuity and take the other information from 
the medical chart.   
 
EYE1: What is the binocular habitual visual acuity at 2 meters (letters correct)?  
                _________________ 
 
EYE2:  What type of eye disease does the person have? 
 1  dry AMD 
 2  wet AMD 
 3 both types of AMD 
 4 not known 
 5  diabetic retinopathy 
 
EYE3:  What was the first date of diagnosis of late-stage AMD or DR?  
 
__________________MM/DD/YY 
 
 
EYE4:  Give all current eye diseases in addition to that stated in EYE2 (only choose 1 
at a time). 
  1.  un-operated cataract 
  2.  diabetic retinopathy 
  3.  glaucoma 
  4.  corneal disease 
  5.  blepharitis 
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  6.  posterior vitreous detachment 
  7.  ocular hypertension 
  8.  none 
  9.  AMD 
 
EYE5:  Give all current eye diseases in addition to AMD (only choose 1 at a time). 
  1.  un-operated cataract 
  2.  diabetic retinopathy 
  3.  glaucoma 
  4.  corneal disease 
  5.  blepharitis 
  6.  posterior vitreous detachment 
  7.  ocular hypertension 
  8.  none 
9.  AMD 
 
 
EYE6:  Give all current eye diseases in addition to AMD (only choose 1 at a time). 
  1.  un-operated cataract 
  2.  diabetic retinopathy 
  3.  glaucoma 
  4.  corneal disease 
  5.  blepharitis 
  6.  posterior vitreous detachment 
  7.  ocular hypertension 
  8.  none 
  9.  AMD 
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Section M: Trial Arm 
 
ARM :  Which group is the person in? 
 
  0.  Control (Delayed Intervention) 
 
1. Experimental (Immediate Intervention) 
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2. Follow-up questionnaire 
  
Instructions to interviewer: 
Please note that only text in bold should be read to patients. Additional questions 
that may be needed for probing are italicized.  
For any question where a preset response was not selected, choose the “other 
codes” that applies (N.B. these codes are to be used as little as possible; before 
using them, try to probing respondent more for an answer): 
 Not applicable (NA): 77 
 Don’t know (DK): 88 
 Refused (R): 99 
 
Contents: 
 Section A: General health status …………………………………………………….xxiv 
Section B: PHQ-9……………………………………………………………………….xxv 
Section C: GAD-7……………………………………………………………………...xxviii 
Section D: Change Questions…………………………………………………………xxix 
Section E: Medication and Adherence……………………………………………….xxx 
Section F: Smoking…………………………………………………………………….xxxii 
Section G: Life Space Questionnaire………………………………………………...xxxii 
Section H: Everyday Activities………………………………………………………xxxvii 
Section I: Social Support…………………………………………………………….xxxvii 
Section J: Self-Efficacy ………………………..…………………………………………xl 
Section K: Treatments…………………………………………………………………..xlii 
Section L: Use of self-care tools……………………………………………………….xliv 
Section M: Satisfaction with Care……………………………………………………..xlvi 
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Section A: Health Status 
Following standard greeting and introduction:  
This is our last interview for this study. It will take about 30 minutes. Some of 
the questions are similar to questions we have asked you previously at the 
start of the study.  
The first questions ask for your view about your health.  
 
If respondent answers don’t know, probe more: 
You don’t know because you don’t understand? Do you have difficulty 
remembering or assessing? When was the last time you did … or felt …? 
 
GHS: Compared to 2 months ago, how would you rate your health in general 
now? 
0 much better now than 2 months ago 
1 somewhat better now than 2 months ago 
2 about the same 
3 somewhat worse than 2 months ago 
4 much worse than 2 months ago 
88 DK 
99 R 
 
Section B: PHQ-9 
Now a few questions on your mood:  
Over the last 2 weeks, how often have you been bothered by any of the 
following problems? For each item, please tell me if you have not been 
bothered at all, if you have been bothered for several days, for more than half 
the days, or been bothered nearly every day. 
Remind respondents of the choices and timeframe when necessary. 
If patient says “1 day” mark as “several days”. 
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 Problem Not at 
all 
Several 
days  
More 
than 
half the 
days 
Nearly 
every 
day 
Other: 
88 DK 
99 R 
a Little interest or pleasure in 
doing things 
0 1 2 3  
b Feeling down, depressed, or 
hopeless 
0 1 2 3  
c Trouble falling or staying 
asleep, or sleeping too much 0 1 2 3  
d Feeling tired or having little 
energy 
0 1 2 3  
e Poor appetite or overeating 0 1 2 3  
f Feeling bad about yourself – 
or that you are a failure or 
have let yourself or your 
family down 
0 1 2 3  
g Trouble concentrating on 
things, such as reading the 
newspaper or watching 
television 
0 1 2 3  
h Moving or speaking so slowly 
that other people could have 
noticed? Or the opposite – 
being so fidgety or restless 
that you have been moving 
around a lot more than usual 
0 1 2 3  
i Thoughts that you would be 
better off dead or of hurting 
yourself in some way 
0 1* 2* 3*  
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ONLY ASK j, k, l if response to 1i is 1, 2, or 3 
 
j. Do you feel these thoughts are something you will act on? 
 0 N   ] → skip to Q2 
 1 Y  
88 DK   ] → skip to Q2 
99 R   ] → skip to Q2 
 
k. Would it be ok for us to let your family doctor know that you have been 
having these feelings and thoughts? 
0 N  
1 Y  
 
l. I would like a psychologist involved with the study to speak with you. 
Would it be ok for me to arrange for you to see the doctor in the next few 
days? 
0 N   
1 Y  
 
I would also like to offer you some telephone contact numbers in case these 
feelings and thoughts get worse and you need help immediately. 
You can call Suicide Action Montreal’s hotline at 514-723-4000 or 1-866-277-
3553 when you are outside of Montreal. 
 
m. What is the patient’s total score?  _______________  
 
*If score is 20 or more, read 1.n and then Q2.  
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1n.    Based on your answers, you may benefit from professional help. Would 
it be ok for us to let your family doctor know about your depressed mood? 
0 N ] → that’s ok, but I would just like to encourage you to speak to a 
medical professional about your mood when you are ready to do so.  
1 Y ]→ OK great. I’ll make sure he/she gets the information.  
 
 
I would also like to offer you a telephone contact number in case these 
feelings and thoughts get worse and you need help immediately. 
Offer emergency contact numbers:  
You can call Suicide Action Montreal’s hotline at 514-723-4000 or 1-866-277-
3553 when you are outside of Montreal. 
 
 
Think about all the problems that you told me about [list problems that the 
patient had from Q1]. How difficult have these problems made it for you to do 
your work, take care of things at home, or get along with other people? 
0 Not difficult at all 
1 Somewhat difficult 
2 Very difficult 
3 Extremely difficult 
77 NA 
88 DK 
99 R 
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Section C: GAD-7 
Over the last 2 weeks, how often have you been bothered by any of the 
following problems? For each item, please tell me if you have not been 
bothered at all, been bothered for several days, been bothered more than half 
the days, or been bothered nearly every day. 
Remind respondents of the choices when necessary 
If patient says “1 day” mark as “several days”. 
 
 Problem Not at 
all 
Several 
days  
More 
than 
half 
the 
days 
Nearly 
every 
day 
Other: 
88 DK 
99 R 
a Feeling nervous, anxious, or 
on edge 
0 1 2 3  
b Not being able to stop or 
control worrying 
0 1 2 3  
c Worrying too much about 
different things 
0 1 2 3  
d Trouble relaxing 0 1 2 3  
e Being so restless that it is 
hard to sit still 
0 1 2 3  
f Becoming easily annoyed or 
irritable 
0 1 2 3  
g Feeling afraid as if 
something awful might 
happen 
0 1 2 3  
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Section D: Change Questions 
Next, I’d like to ask you about changes you may have made in your daily life. 
Since participating in this project, have you tried to change something in 
your daily life to help you feel better?  
0 No   That’s fine. Skip to Section E 
1 Yes 
99 R   skip to Section E 
 Can you please tell me what these changes that you tried to make were?  
PROBE: Anything else you tried to change or changed to help you feel 
better? 
 No Yes DK R 
Your own personal care, for example getting 
dressed and washed every day, eating a more 
healthy diet? 
0 1 88 99 
Being more physically active? 0 1 88 99 
Small chores, like paying bills, housecleaning, 
grocery shopping? 
0 1 88 99 
Involvement with your family and friends? 0 1 88 99 
Making time for personally rewarding activities, like 
taking time for hobbies or activities that you enjoy? 
0 1 88 99 
Trying to set realistic goals? 0 1 88 99 
Thinking realistically? 0 1 88 99 
Trying to solve daily problems effectively? 0 1 88 99 
Remembering to take your prescribed 
medications? 
0 1 88 99 
Using relaxation? 0 1 88 99 
Something else? Specify:  
 
 
0 1 88 99 
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Section E: Medication and Adherence 
List all current prescription medications in the following chart.  
 
*If NONE, skip to Section F* 
 
Name 
# of times/day or 
# of times/week 
1a.  
1b.  
1c.  
1d.  
1e.   
1f.   
1g.   
  
 
2   Now, if we consider all your prescription medicines    SKIP IF NO MEDS 
ARE TAKEN AT ALL  
 
a.   During the past week, did you ever forget to take any of these medicines? 
0 N 
1 Y  
88 DK 
99 R 
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During the past week, were you careless at times about taking any of these 
medicines? 
Were there times when you couldn’t be bothered to take them? 
0 N 
1 Y  
88 DK 
99 R 
 
 During the past week, if you felt better did you sometimes not take or entirely 
stop taking any of these medicines? 
0 N 
1 Y  
88 DK 
99 R 
 
During the past week, if you felt worse when you took any of these 
medicines, did you stop taking them? 
0 N 
1 Y  
88 DK 
99 R 
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Section F: Smoking  
Now I’d like to ask some questions about smoking.  
Do you currently smoke cigarettes? 
0 No   go to SECTION G 
1 Yes 
99 R   go to SECTION G 
 
How many cigarettes a day did you smoke during the last week? 
  
___________cigarettes/day  ASK FOR AN AVERAGE  
88 DK 
99 R 
 
Section G: Life Space Questionnaire 
LS1. During the past 4 weeks, have you been to another room of your home 
besides the room where you sleep? 
0.  No 
1.  Yes  (SKIP TO QUESTION 2) 
99.  Refuse (SKIP TO QUESTION 2) 
 
LS1a.  If yes, how often did you go to another room besides the room where you 
sleep? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
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LS1b.  Did you use technical aids or equipment to get there (for example a cane or 
a walker)? 
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS1c.  Did you need help from another person to get there?  
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS2. During the past 4 weeks, have you been to an area outside your home such 
as your porch, deck, patio, hallway (of an apartment building) or garage in your own 
yard, or driveway? 
0.  No 
1.  Yes (SKIP TO QUESTION 3) 
99.  Refuse (SKIP TO QUESTION 3) 
 
LS2a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
LS2b.  Did you use technical aids or equipment to get there (for example a cane or 
a walker)? 
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
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LS2c.  Did you need help from another person to get there?  
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS3. During the past 4 weeks, have you been to places in your neighbourhood, 
other than your own yard or apartment building? 
0.  No 
1.  Yes (SKIP TO QUESTION 4) 
99.  Refuse (SKIP TO QUESTION 4) 
 
LS3a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
 
LS3b.  Did you use technical aids or equipment to get there (for example a cane or 
a walker)? 
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS3c.  Did you need help from another person to get there?  
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
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LS4. During the past 4 weeks, have you been to places outside your own 
neighbourhood but within your town? 
0.  No 
1.  Yes (SKIP TO QUESTION 5) 
99.  Refuse (SKIP TO QUESTION 5) 
 
LS4a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
 
LS4b.  Did you use technical aids or equipment to get there (for example a cane or 
a walker)? 
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS4c.  Did you need help from another person …?  
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS5. During the past 4 weeks, have you been to places outside your town? 
0.  No 
1.  Yes (SKIP TO NEXT SECTION) 
99.  Refuse (SKIP TO NEXT SECTION) 
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LS5a.  If yes, how often did you go there…? 
1. Less than 1 day / week 
  2. 1-3 days / week 
  3. 4-6 days / week  
  4. Daily  
 
LS5b.  Did you use technical aids or equipment to get there (for example a cane or 
a walker)? 
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
 
LS5c.  Did you need help from another person to get there?  
0.  No 
1.  Yes 
99.  Refuse or Don’t Know 
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Section H: Everyday Activities  
Now I would like to ask you about your daily activities. Please tell me how 
many times you may have engaged in each activity in the past week. 
 
 In the past week, how many times did you… # of times 
 
Other: 
99 R 
1 Visit with family, relatives, friends, or 
neighbours in person? 
  
2 Have a telephone conversation with family, 
relatives, friends, or neighbours? 
 
 
 
3 Contact family, relatives, friends, or 
neighbours through electronic means other 
than telephone? For example, email, text 
messaging, or Facebook.  
  
4 Attend a religious service, such as church or 
synagogue or mosque? 
 
 
 
5 Participate in a social or recreational group 
activity? 
  
6 Take a day trip or overnight trip?   
7 Go to a concert, play, or art exhibition?   
 
 How many DAYS (not “times”!) in the past 
week, did you… 
# of DAYS 
 
Other: 
99 R 
8 Spend time on hobbies such as collecting or 
handiwork? 
  
9 Spend time reading, writing (including time on 
the computer but not work-related), or listening 
to music? 
  
10 Do light housework or gardening?   
11 Do heavy housework or yard work?   
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Do you currently do volunteer work? 
0 No  ]go to next section 
1 Yes  
88 DK ]go to next section 
99 R ]go to next section 
 
How many days in the last week did you engage in volunteer work? 
________ days 
88 DK   
99 R   
 
Section I:  Social Networks 
 
FAMILY/PARTNER: Considering the people to whom you are related either by 
birth or marriage/partnership . . . 
 
LUB1. How many relatives do you see or hear from at least once a month?  
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = 
nine or more 
 
LUB2. How many relatives do you feel close to such that you could call on 
them for help? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = 
nine or more 
 
LUB3. How many relatives do you feel at ease with that you can talk about 
private matters? 
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0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = 
nine or more 
 
FRIENDSHIPS: Considering all of your friends including those who live in 
your neighborhood.  
 
LUB4. How many of your friends do you see or hear from at least once a 
month? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = 
nine or more 
 
LUB5. How many friends do you feel close to such that you could call on 
them for help? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = 
nine or more 
 
LUB6. How many friends do you feel at ease with that you can talk about 
private matters? 
0 =none     1 =one    2 = two       3 = three or four       4 = five thru eight        5 = 
nine or more 
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Section J: Self-Efficacy  
I am going to read to you some more statements that people sometimes 
make when they talk about their mood.  For each statement, please indicate 
how much you agree or disagree with each statement as it applies to you 
personally.  
 
Simplify choices: Do you agree or disagree. If the subject says “I agree” ask “do 
you agree strongly, or just agree”?  
If respondent answers don’t know, probe more: 
You don’t know because you don’t understand? Because you’re not sure? 
Try to narrow down what it is in the statement that makes the patient not know. 
 
 Disagre
e 
strongly 
Disagre
e 
Agre
e 
Agree 
strongly 
Don’t 
Know 
Refuse 
 I am able to carry out 
daily activities that 
can keep my mood 
positive 
0 1 3 4 88 99 
I feel confident that I 
can recognize 
situations that will 
bring my mood down 
0 1 3 4 88 99 
I feel able to meet the 
challenges of 
learning and 
practicing new skills 
to control my mood 
0 1 3 4 88 99 
I am capable of 
stopping my mood 
from becoming 
negative. 
0 1 3 4 88 99 
 
If Q 4 = “agree” or “strongly agree”:  
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5. Can you tell me a bit more about what you do to stop your mood from 
becoming negative?  
Code everything that subject mentions unprompted. Prompt “anything else”?  
1.  Personal care (e.g., getting dressed washed, eating breakfast, eating a more 
healthy diet) 
2.  Being more physically active 
3.  Small duties, like paying bills, housecleaning, grocery shopping 
4.  Involvement with your family and friends 
5.  Making time for personally rewarding activities 
6.  Setting realistic goals  
7.  Thinking more realistically 
8.  Solving problems effectively 
9.  Remembering to take your prescribed medications 
10. Seeking professional counselling or therapy. 
11.  Applying relaxation techniques 
12.  Other, specify_______________________________ 
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Section K: Treatments 
 
Now I’d like to ask you about help that you may have received for emotional 
or mood problems in the last 2 months.  
In the last 2 months, have you received information about emotional or mood 
problems, their treatments, and available services? If the subject asks whether 
to include information from the study: Yes, include information from the study, as 
well as any other information you may have received  
0 No  
1 Yes   
88 DK   
99R  
 
Now please think about therapy or counselling that you may have received 
for emotional or mood problems in the last 2 months. By therapy or 
counselling, I mean discussions with a health professional to learn how to 
deal with your thoughts or behaviours, or to talk through your problems. Did 
you receive such a form of help?   
0 No ] Go to question 3 
1 Yes   
88 DK  ] Go to question 3 
99R ] Go to question 3 
 
2a. when did you start this therapy?  ______________MM/DD/YY 
Now, some questions about medications for emotional or mood problems 
that you might have taken over the last 2 months. Have you taken any 
medications for emotional or mood problems? 
0 N ] Go to question 4 
1 Y  
88 DK ] Go to question 4 
99 R ] Go to question 4 
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3a. when did you start this medication?  ______________ MM/DD/YY 
 
4:  Did you have any procedures done on your eyes during the 8-week follow-
up period?   
  0. No] Go to Next Section 
   1.  Yes 
 
 4a:  What procedures were done?  
  1.  Anti-VEGF injection (e.g. Lucentis, Avastin) 
  2.  Cataract surgery 
  3.  Laser 
  4.  Trabeculectomy 
  5.  Other ___________________________ 
__________________________________________________________________ 
Look at the note on the sticker to see in which group is the patient.  
For Controls:  I see in your record that you are in the control group and that 
you will receive the self-care binder by courier at the address you provided 
when you were recruited.  Would it be OK to mail it to you during the next 
week? 
No   *Let Solmaz know if the answer is no and when to mail  
Yes 
 
For Intervention Group:  
Please continue with sections L and M.  
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Section L: Use of self-care tools 
Now I’d like to ask you about the self-care materials in the binder that you 
received at the beginning of the study. Do you remember receiving this blue 
binder?  
 
Did you look at or use any of the materials in the binder during the last 2 
months? 
0 No  That’s no problem. Skip to next section  
1 Yes 
 
Do you remember what you looked at or used?? Check all that apply and probe 
“Anything else?” 
0 Don’t remember  
1 Movie 
2 Workbook 
3Audio Workbook 
4 Mood monitoring 
5 Relaxation CD 
6 Community resources list 
7 Other resources list (websites/books) 
8 Medications section 
9 Section on eating  
10 Other: _________________ 
 
Some people like to make notes when using the tools in the binder. During 
the last 2 months, did you make notes in your binder, or in another place?  
 0 No  that’s a problem. Skip to SECTION M 
 1 Yes 
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Do you remember which sections you wrote in? Some of the sections included 
worksheets or places to take notes.  We will not be collecting anything you have 
written, but are interested in finding out if people made notes for themselves. Check 
all that apply and probe “Anything else?” 
0 Don’t remember  
1 Workbook 
2 Mood monitoring  
3 Medication sections  
4 Other: ___________ 
 
Did you make notes during the last week?  
 0 No  That’s no problem. Skip to SECTION M 
 1 Yes 
   
Which section have you been writing in? Check all that apply and probe 
“Anything else?” 
0 Don’t remember  
1 Workbook 
2 Mood monitoring  
3 Medication sections  
4 Other: ___________ 
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Section M: Satisfaction with Care 
Now I’d like to ask what you thought about the self-care program we offered you in 
this study. Please be honest, this will help us improve the program.  
Overall, how would you rate the quality of the self-care program you received from 
this self-care project? 
4 Excellent 
3 Good 
2 Fair 
1 Poor 
 
Did the self-care program help you to deal more effectively with your problems? 
4 Yes, it helped a great deal 
3 Yes, it helped somewhat 
2 No, it really didn’t help 
1 No, it seemed to make things worse 
 
If a friend were in need of similar help, would you recommend this program to 
him/her? 
1 No, definitely not 
2 No, I don’t think so 
3 Yes, I think so 
4 Yes, definitely 
 
Please tell me what you liked the most about this program. 
__________________________________________________________________ 
 
And what could be improved?  
__________________________________________________________________ 
